XOMA Corporation (XOMA)
-NasdaqGM 3.95 
0.01(0.25%) 10:12AM EDT - Nasdaq Real Time Price
| Prev Close: | 3.96 |
|---|
| Open: | 3.86 |
|---|
| Bid: | 3.87 x 700 |
|---|
| Ask: | 3.90 x 200 |
|---|
| 1y Target Est: | 5.79 |
|---|
| Beta: | 2.92 |
|---|
| Next Earnings Date: | 5-Aug-13 |
|---|
| Day's Range: | 3.77 - 3.96 |
|---|
| 52wk Range: | 2.25 - 4.40 |
|---|
| Volume: | 124,738 |
|---|
| Avg Vol (3m): | 676,729 |
|---|
| Market Cap: | 327.43M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.88 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- XOMA CORP FinancialsEDGAR Online Financials(Tue, May 14)
- 3 Humongous Health-Care Stocks This Weekat Motley Fool(Sat, May 11)
- XOMA Management Presents at Credit Suisse 2013 Antibody Day (Transcript)at Seeking Alpha(Fri, May 10)
- Positive Data on Celgene's ApremilastZacks(Thu, May 9)
- ARNA Sheds Light on Belviq LaunchZacks(Thu, May 9)
- XOMA price target raised to $6 from $5 at Ladenburgtheflyonthewall.com(Thu, May 9)
- Stock Upgrades: Green Mountain Scales the Summitat Minyanville(Thu, May 9)
- VIVUS Reports Wider LossZacks(Thu, May 9)
- XOMA Corp CEO Discuses Q1 2013 Results - Earnings Call Transcriptat Seeking Alpha(Wed, May 8)
- XOMA Highlights Recent Achievements and Reports Financial Results for First Quarter 2013GlobeNewswire(Wed, May 8)
- XOMA CORP Files SEC form 10-Q, Quarterly ReportEDGAR Online(Wed, May 8)
- Q1 2013 XOMA Earnings Release - After Market CloseCCBN(Wed, May 8)
- XOMA to Present at Credit Suisse 2013 Antibody DayGlobeNewswire(Mon, May 6)
- Incremental Changes in Regulatory Environment Beneficial to Development-Stage Biotech Companies Due to Emphasis on Closer Working Relationships with the FDA and Drug SponsorsWall Street Transcript(Wed, May 1)
- CHMP Backs VIVUS' SpedraZacks(Tue, Apr 30)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 9.84 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.84 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.19 |
|---|
| Mean Recommendation*: | 1.5 |
|---|
| PEG Ratio (5 yr expected): | -0.26 |
|---|
Business Summary
XOMA Corporation discovers and develops antibody-based therapeutics in the United States, Europe, and the Asia Pacific. The company offers ACEON, an angiotensin converting enzyme inhibitor.
View More